Selected hits were evaluated in the TMPRSS2 biochemical assay and the SARS-CoV-2-S pseudotyped particle entry assay, and a number of novel inhibitors were identified, providing a starting point for the further development of therapeutic drug candidates for COVID-19. Here, TMPRSS2 is linked to COVID-19.